1 |
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467.
|
2 |
ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
|
3 |
National Cancer Institute Drug Dictionary (drug id 721679).
|
4 |
ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
|
5 |
Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacok... Biopharm Drug Dispos. 2016 Mar;37(2):93-106.
|
6 |
Clinical pipeline report, company report or official report of CRISPR Therapeutics.
|
7 |
J Clin Oncol 32:5s, 2014 (suppl; abstr 2558).
|
8 |
Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3.
|
9 |
Clinical pipeline report, company report or official report of Seagen.
|
10 |
2011 Pipeline of Seattle Genetics.
|
11 |
SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647.
|
12 |
National Cancer Institute Drug Dictionary (drug id 660730).
|
13 |
Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383.
|
|
|
|
|
|
|